Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, and PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration to optimise size selection for long-read sequencing workflows. PacBio has qualified Yourgene’s LightBench® instrument for size selection of long DNA fragments, enabling high yields for HiFi sequencing data.

Yourgene’s LightBench is an automated electrophoresis instrument, powered by Ranger® Technology. This platform uses a patent-protected, machine-vision algorithm to interpret and control gel electrophoresis in real time. It delivers accurate size selection for human genomic DNA and includes the ability to perform fragment length analysis for additional quality control.

PacBio HiFi sequencing is a single-molecule real-time (SMRT®) sequencing technology. It produces long (1,000 to 20,000+ bases), accurate reads with uniform genomic coverage and native methylation detection for use in applications such as whole genome reconstruction, haplotype phasing, detection of large and complex variants, and epigenetics.

A new Technical Note was released today for PacBio customers titled “Size selection of PacBio SMRTbell® libraries with the LightBench® instrument from Yourgene Health.” The Yourgene LightBench instrument is compatible with the Revio system. The automated LightBench workflow optimises walk away time, offering a scalable size selection solution for the preparation of PacBio SMRTbell sequencing libraries. Results from the initial study* assessing two fragment lengths in 84 human genomic DNA samples from frozen blood for library preparation showed consistent yields for 8 kb or 10 kb size and a zero percent failure rate.

Matthew Nesbitt, Co-Founder of Ranger Technology, at Yourgene Health, said: “PacBio HiFi sequencing technology is a game changer for whole genome applications. High-resolution size selection is crucial to maximising data yields from long-read sequencing and Yourgene is proud to offer researchers a precise and scalable solution with the LightBench.”

*Download the “Size selection of PacBio SMRTbell® libraries with the LightBench® instrument from Yourgene Health.” Technical Note to learn more: https://www.pacb.com/wp-content/uploads/Technical-note-Size-selection-of-PacBio-SMRTbell-libraries-with-the-LightBench-instrument-from-Yourgene-Health.pdf

Visit https://yourgenehealth.com/our-products/instruments/lightbench/ for further information about Yourgene’s LightBench instrument, and https://www.pacb.com/3rd-party-compatible-products/ for details of the PacBio Compatible programme.

Yourgene will also be attending the Association of Molecular Pathology (AMP) 2023 Annual Meeting & Expo in Salt Lake City, UT from 14–18 November. Visit booth #425 to learn more.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”